Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

https://ift.tt/ms2h37D Dupixent ® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission an...

Media Update: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E.coli (ExPEC)

https://ift.tt/aoFfXNw   from Sanofi - Aventis Groupe https://ift.tt/nkCVeNr via IFTTT " May good health envelop you, spurring a q...